Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer.
Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer.
复制标题
DOI：
10.1038/sj.bjc.6605827
复制
发表时间：
2010-09-07
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
白介素6(IL-6)与白介素6受体(sIL-6R)的膜和可溶性结合，可与gp130形成复合体，促进肿瘤细胞的增殖。本研究的目的是探讨结直肠癌患者肿瘤组织中sIL-6R的表达与疾病进展的关系。我们测定了161例接受手术的结直肠癌患者肿瘤和正常粘膜组织中sIL-6R的浓度，以及结肠癌细胞系培养上清中sIL-6R的浓度。免疫组织化学方法检测IL-6、IL-6R和gp130的表达。由sIL-6RCa/N比值和lt；1.0定义的sIL-6R的肿瘤表达缺失与反映疾病进展的因素显著相关，并且不仅是本研究中所有患者的独立预后因素，而且在有疗效的患者中也是如此。结肠癌细胞株在体外产生sIL-6R，细胞因子刺激可刺激癌细胞产生sIL-6R。免疫组织化学结果显示，肿瘤组织中sIL-6R的表达缺失与癌细胞胞浆中IL-6的表达强度呈显著负相关。此外，肿瘤组织中IL-1β的表达与sIL-6R的表达显著相关。SIL-6R在肿瘤中的表达缺失与结直肠癌的进展有关。
Interleukin-6 (IL-6) binds both the membrane and soluble forms of the IL-6 receptor (sIL-6R), which induces a complex with gp130, and proliferation of tumour cells. The aim of this study is to clarify the relationship between tumoral sIL-6R expression and disease progression in colorectal cancer patients. We measured tissue concentrations of sIL-6R in tumour and normal mucosa from 161 colorectal cancer patients undergoing surgery, and in supernatants from colon cancer cell lines. The expression of IL-6, IL-6R and gp130 was evaluated by immunohistochemical analysis. Loss of tumour expression of sIL-6R as defined by sIL-6R Ca/N ratio <1.0 was significantly associated with factors reflecting disease progression, and was an independent prognostic factor not only in all the patients in this study, but also in the patients with curative intent. Colon cancer cell lines produced sIL-6R in vitro, and the production of sIL-6R in cancer cell lines was stimulated by cytokine stimulation. Immunohistochemistry revealed that loss of tumour expression of sIL-6R was significantly inversely correlated with intense IL-6 expression in the cytoplasm of cancer cells. In addition, tumoral IL-1β expression was significantly correlated with sIL-6R expression. Loss of tumour expression of sIL-6R is associated with colorectal cancer disease progression.
登录
查看更多内容
影响因子：
50.3
作者：
Bollrath, Julia;Phesse, Toby J.;Greten, Florian R.
通讯作者：
Greten, Florian R.
影响因子：
64.8
作者：
KAWANO, M;HIRANO, T;KISHIMOTO, T
通讯作者：
KISHIMOTO, T
影响因子：
2.9
作者：
Plushner, Susyn L.
通讯作者：
Plushner, Susyn L.
影响因子：
50.3
作者：
Grivennikov S;Karin E;Terzic J;Mucida D;Yu GY;Vallabhapurapu S;Scheller J;Rose-John S;Cheroutre H;Eckmann L;Karin M
通讯作者：
Karin M
影响因子：
5.4
作者：
MULLBERG, J;SCHOOLTINK, H;ROSEJOHN, S
通讯作者：
ROSEJOHN, S